However, we have found that the ability of compounds to block the effects of multiple sources of Abeta oligomers without having effects on their own is predictive for their ability to restore cognitive function in in vivo models of Alzheimer's disease caused by age-related increases in Abeta (Table S1). Here, APP is linked to early-onset autosomal dominant Alzheimer disease.